BioSpace News Archive

The systemic inflammatory response syndrome treatment market is expected to reach at a CAGR of 7.37% over the forecast period and to hit valuation around US$ 21.36 billion by 2030.

According to Precedence Research, the remote patient monitoring systems market is expected to reach US$ 5,101 million by 2030 and expanding growth at a CAGR of 20% over the forecast period 2022 to 2030.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at two upcoming healthcare conferences.

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management (https://bit.ly/Vibegron).

Stryker’s Joint Replacement Division announced the introduction of the Insignia® Hip Stem, engineered to optimize patient fit and surgeon ease of implantation in muscle-sparing approaches for total hip and hemiarthroplasty procedures, at the American Academy of Orthopaedic Surgeons 2022 Annual Meeting in Chicago.

FUJIFILM Corporation announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, will acquire Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins.

Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities.

A study presented at the American Academy of Orthopaedic Surgeons 2022 Annual Meeting found that Black patients were less likely than white patients to be completely satisfied with the process of care following knee or hip replacement.

POXEL SA (Euronext: POXEL - FR0012432516), today announced its results for the year ended December 31, 2021 and provided a corporate update.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.